22 development-"https:"-"https:"-"https:"-"Newcastle-University" PhD positions in Switzerland
Sort by
Refine Your Search
-
. Empa is a research institution of the ETH Domain. Within our focus research Digital Health Solutions, we develop technologies for continuous long-term monitoring of individuals. At the Biomimetic
-
tasks You will be based at Empa to characterize the physio-chemical properties of plastic particles and will use ice nucleation instruments at ETH Zurich to simulate cloud ice formation processes. Prepare
-
to study and predict. In this four-year SNF-funded project, you will develop data-driven, multiscale simulation methods that combine computer simulations, machine learning, and surrogate models to explore
-
. Empa is a research institution of the ETH Domain. The Laboratory Chemical Energy Carriers and Vehicle Systems Laboratory conducts, develops and optimizes processes for renewable fuels. The group
-
. Empa is a research institution of the ETH Domain. The Urban Energy Systems Laboratory (UESL) pioneers strategies, solutions, and methods to support the development of sustainable, resilient, and
-
. Empa is a research institution of the ETH Domain. The Urban Energy Systems Laboratory (UESL) pioneers strategies, solutions, and methods to support the development of sustainable, resilient, and
-
. Empa is a research institution of the ETH Domain. The Biointerfaces Laboratory is offering a PhD position focused on development of engineered antimicrobial hydrogels. This project aims to tackle
-
development of electrochemical sensors detecting environmental pollutants, providing real-time information for effective management. Past and current work includes electrochemical sensors for airborne virus
-
and flow field interactions Tuning of the CFD models with experimental results Artificial Neural Network training and development Scientific publications in journals and at conferences Supervision
-
. To this end, we will combine high resolution scanning probe microscopy with fluorescence imaging to study amyloid and tau proteins in biofluids from patients to identify those at risk of developing a specific